{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:39:39Z","timestamp":1789580379648,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jtos.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T10:45:49Z","timestamp":1568457949000},"page":"619-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Neurotrophic keratopathy: Pros and cons of current treatments"],"prefix":"10.1016","volume":"17","author":[{"given":"Antonio","family":"Di Zazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Coassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Varacalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Galvagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Vincentis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtos.2019.09.002_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","article-title":"Corneal nerves: structure, contents and function","volume":"76","author":"Muller","year":"2003","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.jtos.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bjo.2009.173799","article-title":"Architecture and distribution of human corneal nerves","volume":"94","author":"Al-Aqaba","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.eye.6700616","article-title":"Neurotrophic keratitis","volume":"17","author":"Bonini","year":"2003","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.jtos.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1002\/jcp.27345","article-title":"In vivo microscopic and optical coherence tomography classification of neurotrophic keratopathy","volume":"234","author":"Mastropasqua","year":"2019","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.jtos.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00055735-199908000-00009","article-title":"Management of neurotrophic keratopathy","volume":"10","author":"Lambiase","year":"1999","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clae.2012.07.009","article-title":"Scleral contact lens management of bilateral exposure and neurotrophic keratopathy","volume":"35","author":"Grey","year":"2012","journal-title":"Contact Lens Anterior Eye"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9394(14)70125-4","article-title":"Amniotic membrane transplantation for persistent epithelial defects with ulceration","volume":"123","author":"Lee","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/01.ico.0000153102.19776.80","article-title":"Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial","volume":"24","author":"Khokhar","year":"2005","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08820538.2013.768678","article-title":"A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis","volume":"29","author":"Turkoglu","year":"2014","journal-title":"Semin Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ophtha.2003.10.019","article-title":"Autologous serum application in the treatment of neurotrophic keratopathy","volume":"111","author":"Matsumoto","year":"2004","journal-title":"Ophthalmology"},{"issue":"6 Suppl","key":"10.1016\/j.jtos.2019.09.002_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S0004-27492008000700010","article-title":"Autologous serum for ocular surface diseases","volume":"71","author":"Quinto","year":"2008","journal-title":"Arq Bras Oftalmol"},{"issue":"8","key":"10.1016\/j.jtos.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","article-title":"Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects","volume":"29","author":"Lopez-Plandolit","year":"2010","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.jtos.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/ICO.0b013e3181a2a7f6","article-title":"Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects","volume":"28","author":"Jeng","year":"2009","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.jtos.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.ophtha.2006.12.014","article-title":"Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis","volume":"114","author":"Yoon","year":"2007","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jtos.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.oftal.2012.09.033","article-title":"[Effectiveness of topical autologous serum treatment in neurotrophic keratopathy]","volume":"88","author":"Guadilla","year":"2013","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"5","key":"10.1016\/j.jtos.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bjo.2009.164780","article-title":"Corneal nerve regeneration in neurotrophic keratopathy following autologous plasma therapy","volume":"94","author":"Rao","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/ICO.0000000000000348","article-title":"Treatment of neurotrophic keratopathy with nicergoline","volume":"34","author":"Lee","year":"2015","journal-title":"Cornea"},{"issue":"Suppl 11","key":"10.1016\/j.jtos.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1097\/ICO.0000000000000587","article-title":"Potential new modes of treatment of neurotrophic keratopathy","volume":"34","author":"Yanai","year":"2015","journal-title":"Cornea"},{"issue":"17","key":"10.1016\/j.jtos.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM199804233381702","article-title":"Topical treatment with nerve growth factor for corneal neurotrophic ulcers","volume":"338","author":"Lambiase","year":"1998","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jtos.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"8181","DOI":"10.1167\/iovs.12-10476","article-title":"Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers","volume":"53","author":"Aifa","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.jtos.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1089\/jop.2017.0010","article-title":"Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent","volume":"33","author":"Guerra","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.09.002_bib22","doi-asserted-by":"crossref","first-page":"3538764","DOI":"10.1155\/2018\/3538764","article-title":"Clinical efficacy of platelet-rich plasma in the treatment of neurotrophic corneal ulcer","volume":"2018","author":"Wrobel-Dudzinska","year":"2018","journal-title":"J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2019.09.002_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1120672117747042","article-title":"Treatment with platelet-rich plasma of surgically related dormant corneal ulcers","volume":"28","author":"Alio","year":"2018","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1167\/iovs.11-7302","article-title":"Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation","volume":"52","author":"Anitua","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","article-title":"Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops","volume":"38","author":"Sanchez-Avila","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2010.05471.x","article-title":"Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4","volume":"1194","author":"Dunn","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.jtos.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/bjo.2007.130013","article-title":"Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy","volume":"92","author":"Yamada","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1006\/bbrc.1998.8704","article-title":"Up-regulation of integrin alpha 5 expression by combination of substance P and insulin-like growth factor-1 in rabbit corneal epithelial cells","volume":"246","author":"Nakamura","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jtos.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yexcr.2003.09.022","article-title":"Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta","volume":"293","author":"Sosne","year":"2004","journal-title":"Exp Cell Res"},{"issue":"5","key":"10.1016\/j.jtos.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1006\/exer.2000.0985","article-title":"Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo","volume":"72","author":"Sosne","year":"2001","journal-title":"Exp Eye Res"},{"issue":"9","key":"10.1016\/j.jtos.2019.09.002_bib31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","article-title":"Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jtos.2019.09.002_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bjo.84.8.826","article-title":"Amniotic membrane transplantation for severe neurotrophic corneal ulcers","volume":"84","author":"Chen","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0161-6420(99)90444-X","article-title":"Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers","volume":"106","author":"Kruse","year":"1999","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jtos.2019.09.002_bib35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/bjo.85.12.1455","article-title":"Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation","volume":"85","author":"Prabhasawat","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2019.09.002_bib36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10384-007-0480-z","article-title":"Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1","volume":"51","author":"Nishida","year":"2007","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2019.09.002_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/ICO.0000000000000759","article-title":"Matrix regeneration therapy: a case series of corneal neurotrophic ulcers","volume":"35","author":"Arvola","year":"2016","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib38","first-page":"200","article-title":"Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus"},{"issue":"3","key":"10.1016\/j.jtos.2019.09.002_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.bmt.1705426","article-title":"Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation","volume":"38","author":"Leite","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtos.2019.09.002_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/01.ico.0000121709.58571.12","article-title":"Multilayer amniotic membrane transplantation in the treatment of corneal perforations","volume":"23","author":"Rodriguez-Ares","year":"2004","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2019.09.002_bib41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jbm.a.30723","article-title":"Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro","volume":"78","author":"Rouet","year":"2006","journal-title":"J Biomed Mater Res A"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012419302010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012419302010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:35:42Z","timestamp":1761539742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012419302010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1542012419302010"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2019.09.002","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurotrophic keratopathy: Pros and cons of current treatments","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}